Clearmind Medicine Inc. (NASDAQ: CMND) filed a European patent application for psychedelic compounds designed to treat Post-Traumatic Stress Disorder and other mental health disorders, the company announced.

The patent application is part of Clearmind's exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. Under the agreement, Clearmind holds global rights to develop, manufacture, and commercialize compounds developed at Yissum.

The filing occurs as President Donald Trump signed an executive order on April 18, 2026, directing federal agencies to accelerate research, development, and regulatory review of psychedelic-based therapies for mental health conditions including PTSD and substance use disorders.

Market data cited by the company indicates the global PTSD treatment market was valued at approximately $18.5 billion in 2025 and is projected to reach $30.2 billion by 2035, representing a compound annual growth rate of 5.0%.

Clearmind describes itself as a clinical-stage biotech company focused on developing non-hallucinogenic, neuroplastogen-derived therapeutics. The company's intellectual property portfolio includes 19 patent families with 31 granted patents.

The Vancouver-based company trades on NASDAQ under the symbol CMND. The information is based on a company press release.